Earnings summaries and quarterly performance for iRhythm Holdings.
Executive leadership at iRhythm Holdings.
Quentin Blackford
Detailed
President and Chief Executive Officer
CEO
CP
Chad Patterson
Detailed
Chief Commercial Officer
DW
Daniel Wilson
Detailed
Chief Financial Officer
MS
Mervin Smith
Detailed
Executive Vice President, Business Operations
MT
Mintu Turakhia
Detailed
Chief Medical Officer, Chief Scientific Officer, and EVP, Product Innovation
PM
Patrick Murphy
Detailed
Chief Business Officer and Chief Legal Officer
SS
Sumi Shrishrimal
Detailed
Executive Vice President, Chief Risk Officer
Board of directors at iRhythm Holdings.
Research analysts who have asked questions during iRhythm Holdings earnings calls.
DR
David Rescott
Baird
6 questions for IRTC
Also covers: HAE, INSP, LIVN +7 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
6 questions for IRTC
Also covers: ABT, AORT, ATRC +14 more
AG
Allen Gong
JPMorgan Chase & Co.
5 questions for IRTC
Also covers: ESTA, GEHC, GKOS +3 more
DR
David Roman
Goldman Sachs Group Inc.
5 questions for IRTC
Also covers: ABT, BAX, BBNX +21 more
NT
Nathan Treybeck
Wells Fargo Securities
5 questions for IRTC
Also covers: ITGR, LMAT, NVRO +2 more
RN
Richard Newitter
Truist Securities
5 questions for IRTC
Also covers: AXNX, BBNX, DXCM +19 more
JY
John Young
Canaccord Genuity - Global Capital Markets
4 questions for IRTC
Also covers: ANGO, CVRX, LUNG +2 more
Marie Thibault
BTIG
4 questions for IRTC
Also covers: ABT, ARAY, ATRC +15 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
3 questions for IRTC
Also covers: ALGN, CBLL, CVRX +17 more
Kallum Titchmarsh
Morgan Stanley
3 questions for IRTC
Also covers: ATEC, AXNX, EMBC +7 more
MK
Macauley Kilbane
William Blair & Company
3 questions for IRTC
Also covers: CBLL, CVRX, GKOS +4 more
DS
David Saxon
Needham & Company
2 questions for IRTC
Also covers: ALC, ALGN, ATEC +11 more
Joanne Wuensch
Citigroup Inc.
2 questions for IRTC
Also covers: ABT, BAX, BDX +19 more
Michael Polark
Wolfe Research
2 questions for IRTC
Also covers: BBNX, BSX, DXCM +13 more
Stephanie Piazzola
Bank of America
2 questions for IRTC
Also covers: BBNX, CBLL, KMTS +3 more
Vijay Kumar
Evercore ISI
2 questions for IRTC
Also covers: A, ABT, AVTR +23 more
Anthony Occhiogrosso
Citigroup Inc.
1 question for IRTC
Also covers: HAE
Bill Plovanic
Canaccord Genuity
1 question for IRTC
Also covers: ANGO, AORT, CBLL +7 more
DS
David Saxon
Needham & Company LLC
1 question for IRTC
Also covers: RXST
DS
David Saxon
Needham
1 question for IRTC
Also covers: AZTA, GKOS
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
1 question for IRTC
Also covers: ATRC, BVS, CBLL +4 more
PB
Philippe Belamant
Truist Securities
1 question for IRTC
Sam Eiber
BTIG, LLC
1 question for IRTC
Also covers: AIRS, APYX, EMBC +8 more
William Plovanic
Canaccord Genuity
1 question for IRTC
Also covers: ATRC, CBLL, CVRX +9 more
Recent press releases and 8-K filings for IRTC.
iRhythm Holdings Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance
IRTC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Holdings reported Q4 2025 revenue of $208.9 million, a 27.1% year-over-year increase, contributing to a full year 2025 revenue of $747.1 million, up 26.2% from 2024.
- The company achieved significant financial milestones in 2025, including its first positive quarterly net income of $5.6 million in Q4 and its first year of positive adjusted EBITDA ($68.9 million) and free cash flow ($34.5 million) for the full year.
- For full year 2026, iRhythm projects revenue between $870 million and $880 million, representing 16%-18% year-over-year growth, and expects adjusted EBITDA margin to expand to 11.5%-12.5% of revenue.
- Strategic growth drivers include expanding primary care penetration, EHR integration (with 75 of its top 100 customers fully integrated), and the anticipated H1 2027 launch of a next-generation MCT device.
Feb 19, 2026, 9:30 PM
iRhythm Holdings Announces Strong Q4 and Full Year 2025 Results with Positive 2026 Outlook
IRTC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Holdings reported full year 2025 revenue of $747.1 million, representing a 26.2% increase year-over-year, and achieved positive free cash flow for the first time in company history.
- For Q4 2025, the company posted global net revenue of $208.9 million and an adjusted EBITDA margin of 16.4%.
- The company provided 2026 revenue guidance of $870-$880 million and adjusted EBITDA margin guidance of 11.5%-12.5%.
- Key operational milestones in 2025 included submitting a 510(k) for Zio® MCT and completing its 12-month FDA remediation plan commitments on time.
Feb 19, 2026, 9:30 PM
iRhythm Technologies Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance
IRTC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Technologies reported Q4 2025 revenue of $208.9 million, representing 27.1% year-over-year growth, and full-year 2025 revenue of $747.1 million, an increase of 26.2% compared to 2024.
- The company achieved its first positive quarterly net income of $5.6 million in Q4 2025 and recorded positive free cash flow of $34.5 million and adjusted EBITDA of $68.9 million (9.2% of revenue) for the full year, marking the first time in company history for both metrics.
- For full-year 2026, iRhythm expects revenue in the range of $870 million to $880 million, representing 16%-18% year-over-year growth, with adjusted EBITDA margin projected to expand to 11.5%-12.5% of revenue.
- iRhythm maintains a 72% market share in long-term continuous monitoring and is progressing with its next-generation MCT device, which is under FDA review for an expected release in the first half of 2027.
Feb 19, 2026, 9:30 PM
iRhythm Holdings Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance
IRTC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Holdings reported a breakout year in 2025, achieving its first positive quarterly net income of $5.6 million in Q4 2025 and generating $34.5 million in free cash flow for the full year, marking the first time in the company's history for both.
- Full year 2025 revenue reached $747.1 million, representing 26.2% growth over 2024, with Q4 revenue at $208.9 million (27.1% year-over-year growth). Adjusted EBITDA for Q4 2025 was $34.3 million (16.4% of revenue), significantly exceeding the 15% goal.
- For full year 2026, the company projects revenue to be between $870 million and $880 million (16%-18% year-over-year growth) and anticipates adjusted EBITDA margin to expand to 11.5%-12.5% of revenue. Gross margin is expected to incrementally improve by 80-100 basis points relative to 2025.
- Strategic highlights include over one-third of 2025 volume originating in primary care settings, and the next-gen MCT device, featuring a 21-day wear time and enhanced algorithms, is currently under FDA review with an expected release in the first half of 2027. The company aims to become a billion-dollar company in 2027.
Feb 19, 2026, 9:30 PM
iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
IRTC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Holdings, Inc. reported fourth quarter 2025 revenue of $208.9 million, a 27.1% increase compared to the fourth quarter of 2024, and achieved net income of $5.6 million, marking the first quarter of positive GAAP net income in Company history.
- For the full year 2025, revenue reached $747.1 million, a 26.2% increase over full year 2024, with a net loss of $44.6 million, representing a $68.7 million improvement compared to full year 2024.
- The company also achieved positive free cash flow of $34.5 million for the full year 2025, the first time in its history.
- iRhythm Holdings provided 2026 guidance, expecting revenue between $870 million and $880 million and an adjusted EBITDA margin of 11.5% to 12.5%.
Feb 19, 2026, 9:14 PM
iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Guidance
IRTC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- iRhythm Holdings reported strong financial performance for Q4 2025, with revenue of $208.9 million (up 27.1% year-over-year) and full-year 2025 revenue of $747.1 million (up 26.2% year-over-year).
- The company achieved significant milestones, including its first quarter of positive GAAP net income at $5.6 million for Q4 2025 and its first year of positive free cash flow at $34.5 million for full-year 2025.
- Adjusted EBITDA reached $34.3 million (16.4% margin) in Q4 2025 and $68.9 million (9.2% margin) for full-year 2025.
- As of December 31, 2025, unrestricted cash, cash equivalents, and marketable securities stood at $583.8 million.
- For full-year 2026, iRhythm expects revenue between $870 million and $880 million and an adjusted EBITDA margin of 11.5% to 12.5%.
Feb 19, 2026, 9:05 PM
iRhythm Technologies Provides 2026 Financial Guidance and Strategic Updates
IRTC
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- iRhythm Technologies expects revenue of $870-$880 million in 2026, representing 17%-18% growth over the anticipated $740 million+ revenue for 2025, and projects Adjusted EBITDA of 11.5%-12.5% for 2026. The company achieved profitability from an adjusted EBITDA perspective and became free cash flow positive for the first time in 2025.
- The company holds 72% market share in the long-term cardiac monitoring (LTCM) space and 15% market share in the mobile cardiac telemetry (MCT) market, which represents a $500 million market opportunity. A new MCT product launch is anticipated in 2027 to enhance competitiveness.
- iRhythm is expanding into the undiagnosed, asymptomatic population, identifying a near-term opportunity of 30 million tests globally, including 27 million undiagnosed individuals in the U.S.. Over one-third of their business now comes through the primary care channel.
- The company leverages AI, including an investment in Lucem, to proactively identify patients with arrhythmias with over 85% accuracy. They are also expanding internationally, currently operating in six countries with less than 1% market share.
Jan 12, 2026, 4:15 PM
IRTC Provides 2025 and 2026 Financial Guidance and Strategic Updates
IRTC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- iRhythm Technologies anticipates full year 2025 revenue of $740+ million and projects 2026 revenue between $870 million and $880 million.
- The company expects to achieve an Adjusted EBITDA margin of 8.25% - 8.75% for 2025 and 11.5% - 12.5% for 2026.
- iRhythm holds a 72% market share in U.S. Long-Term Continuous Monitoring (LTCM) and 15% in Mobile Cardiac Telemetry (MCT), addressing 27+ million potential patients in the U.S..
- Strategic growth initiatives include international expansion into the UK, prioritized EU countries, and Japan, along with the development of a next-gen Zio MCT (510(k) submitted 3Q25) and initial commercial pilots in obstructive sleep apnea.
- 2025 is anticipated to be free cash flow positive for the first time in the company's history.
Jan 12, 2026, 4:15 PM
iRhythm Technologies Provides 2025 Financial Highlights and 2026 Guidance
IRTC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- iRhythm Technologies expects to deliver more than $740 million in revenue for 2025, marking the first time the company will be profitable (adjusted EBITDA positive) and free cash flow positive in its history.
- For 2026, the company forecasts revenue between $870 million and $880 million, representing 17%-18% growth, and anticipates an adjusted EBITDA margin of approximately 11.5%-12.5%.
- The company is expanding into new markets, with over 1/3 of its business now coming through the primary care channel , and is developing a new MCT product expected to launch in 2027 that will monitor for up to 21 days.
- iRhythm sees significant growth opportunities in the undiagnosed population (an estimated 27 million people in the U.S. alone) and international markets where it currently holds less than 1% market share.
Jan 12, 2026, 4:15 PM
iRhythm Reports Strong 2025 Financial Performance and Provides 2026 Guidance
IRTC
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- iRhythm expects to deliver over $740 million in revenue for 2025, exceeding its high-end guidance, and projects $870-$880 million in revenue for 2026, representing 17%-18% growth.
- The company anticipates achieving profitability (adjusted EBITDA) and positive free cash flow for the first time in its history in 2025, with an expected adjusted EBITDA margin of 11.5%-12.5% in 2026.
- iRhythm is expanding its market reach by moving into primary care, which now accounts for over one-third of its business, and is leveraging AI with partners to proactively identify undiagnosed arrhythmia patients with over 85% accuracy.
- A new Zio AT product for the Mobile Cardiac Telemetry (MCT) market, offering 21 days of monitoring, is on file with the FDA and is expected to launch in 2027, a timeline influenced by FDA cybersecurity questions and the success of the current AT product.
Jan 12, 2026, 4:15 PM
Quarterly earnings call transcripts for iRhythm Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more